---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-061308"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:51:57.556002+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Director H. Thomas Watkins to resign; executive compensation and equity grants for 2022

## Summary
- H. Thomas Watkins, director since 2006, will resign at 2022 Annual Meeting; board to shrink from 6 to 5.
- CEO Mihael Polymeropoulos awarded 2021 bonus of $596,744; 2022 base salary $815,140 and target bonus 80%.
- 2022 option grants at $11.36/share: CEO receives 275,000 options and 115,000 RSUs.
- CFO Kevin Moran 2021 bonus $175,473; 2022 base $426,120 and target 45%; option for 77,500 shares.
- Aranthan Jones resigned as Chief Corporate Affairs Officer effective Oct 2021.

## SEC filing metadata
- accession: 0001193125-22-061308
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/d287693d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-061308
- JSON: https://secwatch.observer/filing/0001193125-22-061308.json
- Plain text: https://secwatch.observer/filing/0001193125-22-061308.txt

## Key facts
- Executive change
  Aranthan "AJ" Jones II resigned as Chief Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc..
  - Action: resigned
  - Role: Chief Corporate Affairs and Communications Officer
  source text: Mr. Jones resigned as the Company’s Chief Corporate Affairs and Communications Officer effective as of October 26, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm
- Executive change
  H. Thomas Watkins resigned as Class I director at Vanda Pharmaceuticals Inc..
  - Action: resigned
  - Role: Class I director
  source text: H. Thomas Watkins notified the Board that he would resign from the Board as a Class I director effective as of the Company’s 2022 Annual Meeting of Stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000119312522061308/0001193125-22-061308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.